AdultPediatricGeriatricDosage Forms & Strengths tablet 10 mg Depression 10 mg PO q6-12hr, increase by 10 mg/day q2-4d to 40 mg/day PO divided q6-12hr by end of first week After first week, may increase by up to 20 mg/week to maximum 60 mg/day; decrease dose to maintenance dose once maximum effect achievedSafety and efficacy not establishedDepression 10 mg PO q6-12hr, increase by 10 mg/day q2-4d to 40 mg/day PO divided q6-12hr by end of first week After first week, may increase by up to 20 mg/week to maximum 60 mg/day; decrease dose to maintenance dose once maximum effect achievedInteraction CheckerEnter a drug name and isocarboxazidNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (92)amitriptylineisocarboxazid and amitriptyline both increase serotonin levels. Contraindicated.amoxapineisocarboxazid and amoxapine both increase serotonin levels. Contraindicated.apraclonidineapraclonidine, isocarboxazid. Mechanism: unknown. Contraindicated. Contraindicated in mfr. prescribing info.isocarboxazid, apraclonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.armodafinilisocarboxazid increases effects of armodafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.atomoxetineisocarboxazid increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.benzphetamineisocarboxazid increases effects of benzphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.brimonidineisocarboxazid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.bupropionisocarboxazid and bupropion both increase dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropionbuspironeisocarboxazid and buspirone both increase serotonin levels. Contraindicated.isocarboxazid, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.caffeineisocarboxazid increases effects of caffeine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.carbamazepinecarbamazepine increases toxicity of isocarboxazid by unknown mechanism. Contraindicated. D/C MAO inhibitor 2 weeks before.citalopramisocarboxazid and citalopram both increase serotonin levels. Contraindicated. At least 2 weeks should elapse between discontinuation of MAOI therapy and the start of citalopram therapy, and at least 2 weeks between discontinuation of citalopram therapy and commencement of MAOI therapy.clomipramineisocarboxazid and clomipramine both increase serotonin levels. Contraindicated.cyclobenzaprineisocarboxazid and cyclobenzaprine both increase serotonin levels. Contraindicated. Do not coadminister cyclobenzaprine with MAOIs or within 14 days of discontinuing an MAOIcyproheptadineisocarboxazid, cyproheptadine. Other (see comment). Contraindicated. Comment: MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines. Cyproheptadine may diminish the serotonergic effect of MAO inhibitors.desipramineisocarboxazid and desipramine both increase serotonin levels. Contraindicated.desvenlafaxineisocarboxazid and desvenlafaxine both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drugdeutetrabenazineisocarboxazid, deutetrabenazine. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Deutetrabenazine should not be used in combination with an MAOI, or within 14 days of discontinuing therapy with an MAOI.dexfenfluramineisocarboxazid increases effects of dexfenfluramine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dexmethylphenidateisocarboxazid increases effects of dexmethylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dextroamphetamineisocarboxazid increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dextroamphetamine transdermalisocarboxazid increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration.dextromethorphanisocarboxazid and dextromethorphan both increase serotonin levels. Contraindicated.diethylpropionisocarboxazid increases effects of diethylpropion by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dobutamineisocarboxazid increases effects of dobutamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dopamineisocarboxazid increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dosulepinisocarboxazid and dosulepin both increase serotonin levels. Contraindicated.doxepinisocarboxazid and doxepin both increase serotonin levels. Contraindicated.duloxetineisocarboxazid and duloxetine both increase serotonin levels. Contraindicated.entacaponeentacapone, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and entacapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.ephedrineisocarboxazid increases effects of ephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.epinephrineisocarboxazid increases effects of epinephrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.epinephrine inhaledisocarboxazid and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of epinephrine inhaled with MAOIs or within 2 weeks after discontinuing an MAOI is contraindicated.escitalopramisocarboxazid and escitalopram both increase serotonin levels. Contraindicated.fenfluramineisocarboxazid increases effects of fenfluramine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.fenfluramine, isocarboxazid. Either increases effects of the other by serotonin levels. Contraindicated. Coadministration with drugs that increase serotonin may increase the risk of serotonin syndrome. Do not use concomitantly or within 14 days of MAOIs.fentanylisocarboxazid increases toxicity of fentanyl by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fentanyl intranasalisocarboxazid increases toxicity of fentanyl intranasal by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fentanyl transdermalisocarboxazid increases toxicity of fentanyl transdermal by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fentanyl transmucosalisocarboxazid increases toxicity of fentanyl transmucosal by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fluoxetineisocarboxazid and fluoxetine both increase serotonin levels. Contraindicated.fluvoxaminefluvoxamine and isocarboxazid both increase serotonin levels. Contraindicated.imipramineisocarboxazid and imipramine both increase serotonin levels. Contraindicated.isomethepteneisocarboxazid, isometheptene. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hypertension, V tach.isoproterenolisocarboxazid increases effects of isoproterenol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.levodopaisocarboxazid, levodopa. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.levodopa inhaledlevodopa inhaled increases effects of isocarboxazid by dopaminergic effects. Contraindicated. Levodopa may enhance risk for acute hypertensive episode if coadministered with nonselective MAOIs. Discontinue use of any nonselective MAO inhibitors at least 2 weeks before initiating levodopa inhaled.levomilnacipranisocarboxazid and levomilnacipran both increase serotonin levels. Contraindicated. Do not use MAOIs intended to treat psychiatric disorders with levomilnacipran or within 7 days of stopping levomilnacipran due to an increased risk of serotonin syndromelisdexamfetamineisocarboxazid, lisdexamfetamine. Either increases effects of the other by serotonin levels. Contraindicated. Do not use amphetamines during and within 14 days of discontinuation of monoamine oxidase inhibitors. .lofepramineisocarboxazid and lofepramine both increase serotonin levels. Contraindicated.maprotilineisocarboxazid and maprotiline both increase serotonin levels. Contraindicated.meperidineisocarboxazid and meperidine both increase serotonin levels. Contraindicated.isocarboxazid increases toxicity of meperidine by unknown mechanism. Contraindicated.methamphetamineisocarboxazid increases effects of methamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.methylenedioxymethamphetamineisocarboxazid increases effects of methylenedioxymethamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.methylphenidateisocarboxazid increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.methylphenidate transdermalmethylphenidate transdermal and isocarboxazid both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.midodrineisocarboxazid increases effects of midodrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.milnacipranisocarboxazid and milnacipran both increase serotonin levels. Contraindicated.modafinilisocarboxazid increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.nefazodoneisocarboxazid and nefazodone both increase serotonin levels. Contraindicated.norepinephrineisocarboxazid increases effects of norepinephrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.nortriptylineisocarboxazid and nortriptyline both increase serotonin levels. Contraindicated.opicaponeopicapone, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and opicapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.ozanimodisocarboxazid and ozanimod both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of ozanimod with MAO-B inhibitors may decrease exposure of the active metabolites of ozanimod, which may inhibit MAO. The potential for a clinical interaction with MAO inhibitors has not been studied; however, the increased risk of nonselective MAO inhibition may lead to a hypertensive crisis. Allow at least 14 days to elapse between discontinuing ozanimod and initiating with MAO inhibitors.paroxetineisocarboxazid and paroxetine both increase serotonin levels. Contraindicated.phendimetrazineisocarboxazid increases effects of phendimetrazine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenelzineisocarboxazid and phenelzine both increase serotonin levels. Contraindicated.phentermineisocarboxazid increases effects of phentermine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenylephrineisocarboxazid increases effects of phenylephrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenylephrine POisocarboxazid increases effects of phenylephrine PO by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.procarbazineisocarboxazid and procarbazine both increase serotonin levels. Contraindicated. At least 2 weeks should elapse between discontinuation of one MAOI and initiation of therapy with the other.propylhexedrineisocarboxazid increases effects of propylhexedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.protriptylineisocarboxazid and protriptyline both increase serotonin levels. Contraindicated.pseudoephedrineisocarboxazid increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.rasagilinerasagiline and isocarboxazid both increase serotonin levels. Contraindicated. Increased risk of hypertensive crisis. At least 14 days should elapse between discontinuation of rasagiline and initiation of another MAOI or discontinuation of another MAOI and initiation of rasagiline.safinamideisocarboxazid, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Coadministration increases risk of nonselective MAO inhibition, that may lead to hypertensive crisis. At least 14 days should elapse between discontinuating safinamide and initiating MAOIs.selegilineselegiline and isocarboxazid both increase serotonin levels. Contraindicated.selegiline transdermalselegiline transdermal and isocarboxazid both increase serotonin levels. Contraindicated.serdexmethylphenidate/dexmethylphenidateisocarboxazid increases effects of serdexmethylphenidate/dexmethylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.sertralineisocarboxazid and sertraline both increase serotonin levels. Contraindicated.solriamfetolisocarboxazid will increase the level or effect of solriamfetol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Do no use solriamfetol during and/or within 14 days of discontinuing MAOI treatment. MAOIs irreversibly inhibit the enzyme monamine oxidase, an enzyme involved in the degradation of various monoamines, including dopamine and norepinephrine. Solriamfetol increases synaptic dopamine and norepinephrine.St John's Wortisocarboxazid and St John's Wort both increase serotonin levels. Contraindicated.tetrabenazinetetrabenazine, isocarboxazid. Other (see comment). Contraindicated. Comment: Risk of acute hypertensive episode; separate by 14 d. Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.tolcaponetolcapone, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and tolcapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.tranylcypromineisocarboxazid and tranylcypromine both increase serotonin levels. Contraindicated.trazodoneisocarboxazid and trazodone both increase serotonin levels. Contraindicated.trimipramineisocarboxazid and trimipramine both increase serotonin levels. Contraindicated.tyramineisocarboxazid increases effects of tyramine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Tyramine containing foods include cheese, red wine, caviar, herring, canned figs, fermented meats, fava beans, yeast extracts, miso, avocado.venlafaxineisocarboxazid and venlafaxine both increase serotonin levels. Contraindicated.vilazodoneisocarboxazid, vilazodone. Either increases toxicity of the other by serotonin levels. Contraindicated. Coadministration with MAO-A inhibitors are contraindicated. Do not prescribe vilazodone within 14 days of discontinuing or starting an MAO inhibitor.vortioxetineisocarboxazid, vortioxetine. Either increases effects of the other by serotonin levels. Contraindicated.xylometazolineisocarboxazid increases effects of xylometazoline by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.yohimbineisocarboxazid increases effects of yohimbine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.Serious - Use Alternative (106)5-HTPisocarboxazid and 5-HTP both increase serotonin levels. Avoid or Use Alternate Drug.albuterolisocarboxazid increases effects of albuterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.alfentanilisocarboxazid increases toxicity of alfentanil by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.almotriptanalmotriptan and isocarboxazid both increase serotonin levels. Avoid or Use Alternate Drug.isocarboxazid increases levels of almotriptan by decreasing metabolism. Contraindicated.amobarbitalisocarboxazid, amobarbital. Other (see comment). Contraindicated. Comment: CNS depressants such as barbiturates should not be used in combination with isocarboxazid.arformoterolisocarboxazid increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.belladonna and opiumisocarboxazid increases toxicity of belladonna and opium by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.benzhydrocodone/acetaminophenisocarboxazid increases toxicity of benzhydrocodone/acetaminophen by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while